Author's Accepted Manuscript

Risk stratification of newly diagnosed prostate cancer with genomic platforms

Michael S. Leapman, MD, Peter R. Carroll, MD, MPH

PII: S2352-0779(16)30209-6
DOI: 10.1016/j.urpr.2016.06.008
Reference: URPR 227

To appear in: *Urology Practice*
Accepted Date: 28 June 2016

Please cite this article as: Leapman MS, Carroll PR, Risk stratification of newly diagnosed prostate cancer with genomic platforms, *Urology Practice* (2016), doi: 10.1016/j.urpr.2016.06.008.

DISCLAIMER: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our subscribers we are providing this early version of the article. The paper will be copy edited and typeset, and proof will be reviewed before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to The Journal pertain.

All press releases and the articles they feature are under strict embargo until uncorrected proof of the article becomes available online. We will provide journalists and editors with full-text copies of the articles in question prior to the embargo date so that stories can be adequately researched and written. The standard embargo time is 12:01 AM ET on that date.

ACCEPTED MANUSCRIPT

Risk stratification of newly diagnosed prostate cancer with genomic platforms

Michael S. Leapman MD and Peter R. Carroll MD, MPH

Department of Urology, UCSF – Helen Diller Family Comprehensive Cancer Center
University of California San Francisco

ACCEPTED MANUSCRIPT

Corresponding Author:

Peter R. Carroll, MD MPH
Professor and Chair
UCSF Department of Urology
550 16th Street 6th floor, Box 1695
San Francisco, CA 94143
Email: peter.carroll@ucsf.edu

Download English Version:

https://daneshyari.com/en/article/8830328

Download Persian Version:

https://daneshyari.com/article/8830328

Daneshyari.com